Society of Hematologic Oncology (SOHO), Poster, September 3, 2025
Effect of TERN-701 on Transporter and Cytochrome P450 Probe Substrates and the Effect of Acid-Reducing Agents on TERN-701 Pharmacokinetics
DOWNLOADscientific presentations & publications
oncology
Society of Hematologic Oncology (SOHO), Poster, September 3, 2025
Characterization & Efficacy of TERN-701 In Pre-clinical Models of Chronic Myeloid Leukemia
DOWNLOADEuropean Hematology Association (EHA), Oral Presentation, June 13, 2025
Characterization & Efficacy of TERN-701 in Pre-Clinical Models of Chronic Myeloid Leukemia
DOWNLOADSociety of Hematologic Oncology (SOHO), Poster, September 4, 2024
CARDINAL: A Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Chronic Myeloid Leukemia
DOWNLOADSociety of Hematologic Oncology (SOHO), Poster, September 4, 2024
Safety, Tolerability, Pharmacokinetics, and the Effect of Food on TERN-701, an Oral Allosteric BCR-ABL Tyrosine Kinase Inhibitor, in Healthy Participants
DOWNLOADSociety of Hematologic Oncology (SOHO), Poster, September 6, 2023
The novel BCR::ABL1 allosteric inhibitor TERN-701 is potent against mutations resistant to active site tyrosine kinase inhibitors (TKIs) and acts synergistically with TKIs in BCR::ABL1+ cancer cell lines
DOWNLOADAmerican Society for Pharmacology and Experimental Therapeutics (ASPET), Poster, May 18, 2023
Efficacy of TERN-701 in tumor xenograft models, a new investigational allosteric ABL1 kinase inhibitor as a potential treatment for CML
DOWNLOAD
metabolic
American Diabetes Association (ADA), Oral Presentation, June 23, 2025
Efficacy and Safety of Oral Small Molecule GLP-1 Receptor Agonist TERN-601 in Healthy Participants with Obesity or Overweight – A First-In-Human Study
DOWNLOADAmerican Diabetes Association (ADA), Poster, June 22, 2025
No Effect of Food or Proton Pump Inhibitor on the Pharmacokinetics of TERN-601, An Oral Small Molecule GLP-1 Receptor Agonist
DOWNLOADNature Medicine, Publication, June 11, 2025
TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial
DOWNLOADKeystone Symposium: Obesity & Adipose Tissue, Poster, February 25, 2025
TERN-501 Enhances Weight Loss of Low Dose Oral GLP-1R Agonist in Obese Mice
DOWNLOADAmerican Diabetes Association (ADA), Poster, June 21, 2024
TERN-501 Enhances Weight Loss Efficacy of a GLP-1R Agonist in Obese Mice via Increased Fat Mass Loss without Additional Loss of Lean Mass
DOWNLOADEuropean Association for the Study of the Liver (EASL), Poster, June 8, 2024
TERN-501, a highly selective thyroid hormone receptor β agonist, significantly improved MRI-PDFF, cT1, and liver volume in clinically relevant patient populations with presumed MASH: subgroup analyses from a 12-week phase 2a trial
DOWNLOADEuropean Association for the Study of the Liver (EASL), Poster, June 8, 2024
Sex hormone binding globulin as an effective predictor of treatment response to TERN-501, a potent, highly selective thyroid hormone receptor β agonist: post-hoc analyses from a 12-week phase 2a trial
DOWNLOADAmerican Association for the Study of Liver Diseases (AASLD), Oral Presentation, November 13, 2023
Topline Results from a 12-Week Phase 2a Trial (DUET) Evaluating TERN-501, a Highly Selective Thyroid Hormone Receptor (THR) β Agonist, Either as Monotherapy or in Combination with TERN-101, a Nonsteroidal Farnesoid X Receptor (FXR) Agonist, Demonstrated Significant Reductions in MR-Based Liver Fat Content and Fibroinflammation in Patients with Presumed MASH
DOWNLOADAmerican Association for the Study of Liver Diseases (AASLD), Poster, November 11, 2023
A Stepwise Screening Approach Using Noninvasive Tests To Identify Phenotypic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients With Fibrosis For Clinical Trials
DOWNLOADAmerican Association for the Study of Liver Diseases (AASLD), Poster, November 5, 2022
Thyroid Hormone Beta Receptor Agonist TERN-501 Demonstrates Dose- and Exposure-Dependent Increases in Sex Hormone Binding Globulin with Associated Decreases in Atherogenic Lipids in Healthy Subjects
DOWNLOADAmerican Association for the Study of Liver Diseases (AASLD), Poster, November 5, 2022
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Phase 2a Study with Factorial Design to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of TERN-501 Alone and in Combination with TERN-101 in Patients with NASH
DOWNLOADEuropean Association for the Study of the Liver (EASL), Oral Presentation, June 25, 2022
Multiple doses of thyroid hormone receptor-beta agonist TERN-501 were well-tolerated and resulted in significant dose-dependent changes in serum lipids and sex hormone binding globulin in a first-in-human clinical study
DOWNLOAD
